NEW YORK – nFerence on Thursday said it has partnered with BeiGene to study treatment patterns and outcomes in B-cell cancers using nFerence's Agentic artificial-intelligence platform.
Agentic AI is a form of generative AI that uses reasoning and iterative planning to solve complex problems. It ingests data from various sources and uses a large language model to generate solutions while coordinating separate, specialized models for specific functions like content creation or visual processing. It then executes a task based on the plan it developed and uses data generated from the process to learn and adapt to become more effective over time.
Thousands of patients in the US every year are diagnosed with B-cell cancers, including chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). BeiGene and nFerence plan to use its Agentic AI platform to review more than 700 patient charts to find real-world treatment patterns.
"Through this collaboration with BeiGene, we aim to uncover valuable real-world insights into treatment patterns and outcomes, helping refine clinical practices," nFerence Cofounder and CSO Venky Soundararajan said in a statement. "Our goal is to generate a comprehensive view of real-world outcomes that enhances clinical decisions, leading to more effective, personalized care for patients with CLL, SLL, and other B-cell malignancies."
nFerence signed an agreement last month with Valo Health to support target discovery, clinical translation, and biomarker discovery for Valo's drug development programs. The Cambridge, Massachusetts-based firm is also working with Parabilis Medicines on target and clinical biomarker identification within a clinical trial of its investigational therapy, FOG-001, in colorectal cancer and with Takeda to personalize treatment options for inflammatory bowel disease.